Janet O’Neil

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 108 citations

Neurodegenerative Diseases, Neuropsychology, Alzheimer's Disease +11

Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction

Eugene Dula, William Keating, Paul Siami et al. · Urology · 2000 · 101 citations

Urology, Erectile Dysfunction, Medicine +6

Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed‐release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis

David C. Metz, Colin W. Howden, María Claudia Pérez et al. · Alimentary Pharmacology & Therapeutics · 2009 · 67 citations

Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release

Ronnie Fass, John M. Inadomi, Cong Han et al. · Clinical Gastroenterology and Hepatology · 2011 · 59 citations

Pharmacology, Pharmacotherapy, Medicine +1

The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial

Daniel K. Burns, Carl Chiang, Kathleen A. Welsh‐Bohmer et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2019 · 41 citations · Full text